Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Venetoclax

FDA-approved product (tablet, oral), marketed as Venclexta, Venetoclax.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Venetoclax
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
BCL-2 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Venetoclax in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Venetoclax with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT07582159 · start 2026-12-19

    Registered record
    Registry ID
    NCT07582159
    Conditions
    Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
    Interventions
    Acalabrutinib; Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Positron Emission Tomography; Tafasitamab; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-19
    Completion
    2029-04-14
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
    InterventionAcalabrutinib; Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML

    NCT07828535 · start 2026-10-30

    Registered record
    Registry ID
    NCT07828535
    Conditions
    Acute Myeloid Leukemia (AML)
    Interventions
    Liposome Mitoxantrone; Venetoclax; Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2032-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML)
    InterventionLiposome Mitoxantrone; Venetoclax; Azacitidine
    PhasePhase 1
    Registry statusNot yet recruiting

  • Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    NCT07734038 · start 2026-10-01

    Registered record
    Registry ID
    NCT07734038
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Magnetic Resonance Imaging; Venetoclax; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2027-12-31
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +3 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

    NCT06903702 · start 2026-08-04

    Registered record
    Registry ID
    NCT06903702
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Azacitidine (AZA); Venetoclax; Allogeneic hematopoietic stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2026-08-04
    Completion
    2027-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionAzacitidine (AZA); Venetoclax; Allogeneic hematopoietic stem cell transplantation
    PhasePhase 2
    Registry statusWithdrawn

  • Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax

    NCT07691047 · start 2026-07-31

    Registered record
    Registry ID
    NCT07691047
    Conditions
    Chronic Lymphoid Leukemia
    Interventions
    Cervical, Thoracic, Abdominal, and Pelvic CT Scan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-31
    Completion
    2029-09-30
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphoid Leukemia
    InterventionCervical, Thoracic, Abdominal, and Pelvic CT Scan
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

    NCT05554419 · start 2026-07-01

    Registered record
    Registry ID
    NCT05554419
    Conditions
    Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Secondary Acute Myeloid Leukemia
    Interventions
    Azacitidine; Bone Marrow Aspiration and Biopsy; Cytarabine; Echocardiography Test; Liposome-encapsulated Daunorubicin-Cytarabine; Multigated Acquisition Scan; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2026-08-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy +1 more
    InterventionAzacitidine; Bone Marrow Aspiration and Biopsy; Cytarabine; Echocardiography Test +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

    NCT07664839 · start 2026-07-01

    Registered record
    Registry ID
    NCT07664839
    Conditions
    Acute Myeloid Leukemia; NPM1 Mutation; IDH1 Mutation; IDH2 Mutation
    Interventions
    VEN combined with azacitidine; Cytarabine plus Daunorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2032-05-31
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; NPM1 Mutation; IDH1 Mutation; IDH2 Mutation
    InterventionVEN combined with azacitidine; Cytarabine plus Daunorubicin
    PhasePhase 2
    Registry statusNot yet recruiting

  • Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML

    NCT07572695 · start 2026-04-30

    Registered record
    Registry ID
    NCT07572695
    Conditions
    Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    Interventions
    Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-04-30
    Completion
    2028-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    InterventionHaploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    PhaseNot recorded
    Registry statusNot yet recruiting

  • CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

    NCT07294677 · start 2026-03-17

    Registered record
    Registry ID
    NCT07294677
    Conditions
    Leukemia; Lymphoma
    Interventions
    Capivasertib; Venetoclax; Rituximab; Blinatumomab; Nelarabine; mini-hyperCVD
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-03-17
    Completion
    2032-03
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    InterventionCapivasertib; Venetoclax; Rituximab; Blinatumomab +2 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

    NCT07486479 · start 2026-03-10

    Registered record
    Registry ID
    NCT07486479
    Conditions
    Acute Myeloid Leukemia (AML)
    Interventions
    Mitoxantrone Hydrochloride Liposome; Venetoclax; Azacitidine; Idarubicin; Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03-10
    Completion
    2027-12-31
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML)
    InterventionMitoxantrone Hydrochloride Liposome; Venetoclax; Azacitidine; Idarubicin +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

    NCT07277231 · start 2026-01-22

    Registered record
    Registry ID
    NCT07277231
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Sonrotoclax; Zanubrutinib; Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-22
    Completion
    2031-11
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionSonrotoclax; Zanubrutinib; Acalabrutinib; Venetoclax
    PhasePhase 3
    Registry statusRecruiting

  • Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT

    NCT07319793 · start 2026-01-01

    Registered record
    Registry ID
    NCT07319793
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndromes (MDS)
    Interventions
    Prophylactic DLI; Preemptive DLI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-01-01
    Completion
    2028-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndromes (MDS)
    InterventionProphylactic DLI; Preemptive DLI
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

    NCT07183878 · start 2025-08-20

    Registered record
    Registry ID
    NCT07183878
    Conditions
    Acute Myeloid Leukemia; High-Risk Acute Myeloid Leukemia; Myelodysplastic Syndromes; High-Risk Myelodysplastic Syndromes
    Interventions
    Venetoclax; None-placebo; Busulfan (BU)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-08-20
    Completion
    2028-08-20
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; High-Risk Acute Myeloid Leukemia; Myelodysplastic Syndromes; High-Risk Myelodysplastic Syndromes
    InterventionVenetoclax; None-placebo; Busulfan (BU)
    PhaseNot applicable
    Registry statusRecruiting

  • Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

    NCT06672146 · start 2025-05-16

    Registered record
    Registry ID
    NCT06672146
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine; Enasidenib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-16
    Completion
    2027-03-31
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

    NCT07152041 · start 2025-03-28

    Registered record
    Registry ID
    NCT07152041
    Conditions
    Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventions
    olverembatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-28
    Completion
    2030-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventionolverembatinib
    PhasePhase 3
    Registry statusRecruiting